Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

At this time, I would like to welcome everyone to the Biogen third quarter 2024 earnings call and business update. [Operator ...

Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling. Meanwhile, some companies such as Biogen, U.S. Bancorp ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

We recently compiled a list of the 10 Best QQQ Stocks to Buy According to Analysts. In this article, we are going to take a ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ...

For the quarter ended September 2024, Biogen Inc. (BIIB) reported revenue of $2.47 billion, down 2.6% over the same period last year. EPS came in at $4.08, compared to $4.36 in the year-ago quarter.